



107 College Road East  
Princeton, NJ 08540  
Tel: 609.608.1246  
jcalvarez@drreddys.com

**VIA EMAIL – AGO.highcostprescriptiondrugs@vermont.gov**

January 2, 2020

Vermont Attorney General’s Office  
109 State Street  
Montpelier, VT 05609

**RE: New Prescription Drug – 30-Day Notice**

Dear Sir or Madam,

Dr. Reddy’s Laboratories, Inc. (“Dr. Reddy’s”) is providing this information in accordance with 18 V.S.A. § 4637(c), which requires that prescription drug manufacturers notify the Office of the Attorney General and to provide certain information following the release of a drug in the commercial market whose Wholesale Acquisition Cost (“WAC”) exceeds the threshold set for a specialty drug under the Medicare Part D Program.

NDC:	43598-0853-30 43598-0851-30
Product Description:	Deferasirox Film coated tablets 90MG Deferasirox Film coated tablets 360MG
Date of Introduction to Market:	12/05/2019 (for both SKUs)
WAC:	\$190.03 per 30 pill count bottle (for Deferasirox FCT 90MG) \$760.08 per 30 pill count bottle (for Deferasirox FCT 360MG)
Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	Dr. Reddy's did not develop direct-to-consumer marketing or paid advertising for the product. In addition, we do not directly promote the product to physicians. To the extent that our purchasing agents or buyers are licensed pharmacists or HCPs we may provide them with product sell sheets which include product name, product description, available pack information, and order entry details. The spend on such materials is less than \$5,000 per year.
The estimated volume of patients that may be prescribed the drug	Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis. Specifically, Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its Deferasirox FCT product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; and (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient.
Was the drug granted breakthrough therapy designation by the federal Food and Drug Administration (FDA) prior to final approval?	No

Did the drug receive a priority review by the federal Food and Drug Administration prior to final approval?	No
The date and price of acquisition if the drug was not developed by the manufacturer	N/A

Please do not hesitate to contact us if you have any questions.

Regards,



Juan Alvarez  
Government Contracts & Pricing  
Dr. Reddy's Laboratories, Inc.